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Primary biliary cirrhosis (PBC) is characterized by chronic destructive cholangitis, 
which is associated with the reduced expression of an anti-inflammatory molecule, 
peroxisome proliferator-activated receptor-γ (PPARγ), in intrahepatic bile ducts. We 
previously demonstrated the anti-inflammatory effects of PPARγ ligands using cultured 
human biliary epithelial cells. In this study, we evaluated the effectiveness of PPARγ 
ligand against peribiliary inflammation in vivo. As an animal model of PBC, we used 
MRL/lpr mice in which a PBC-like cholangitis occurs naturally. Anti-inflammatory 
effects of the intraperitoneal administration of a PPARγ ligand, the prostaglandin D 
metabolite 15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2), were evaluated. In untreated 
mice, portal inflammation including cholangitis was found to some degree in the 
majority of portal tracts. In mice given a high-dose group, the degree of portal 
inflammation was significantly reduced and mice mostly lacking portal inflammation 
and cholangitis were also found. T cell numbers in portal tracts were markedly 
decreased in the high-dose group, compared with controls, whereas there was no 
significant difference in terms of B cells and macrophages. This study is the first to 
assess the therapeutic potential of a PPARγ ligand against portal inflammation including 
cholangitis. Anti-inflammatory effects of PPARγ ligands may prevent the progression of 
cholangiopathy in PBC patients. 
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INTRODUCTION 
 
Primary biliary cirrhosis (PBC) is characterized by the progressive loss of bile 
ducts, mainly interlobular bile ducts.1,2 Infectious and xenobiotics components and 
abnormal immune responses are implicated in the etiopathogenesis of PBC.3-8 Our 
previous study showed that biliary epithelial cells (BECs) of the intrahepatic bile ducts 
possess an innate immune machinery consisting of bacterial recognition molecules, 
Toll-like receptors (TLRs), and can respond to lipopolysaccharide (LPS) followed by 
nuclear factor-κB (NF-κB) and inflammatory cytokines in BECs.9,10 Under physiological 
conditions, however, the intrahepatic biliary epithelium lacks any inflammatory 
reactions in vivo, though several pathogen-associated molecular patterns (PAMPs) 
including bacterial DNA and LPS exist in bile,9,11 suggesting that BECs possess the 
capacity to attenuate cytokine gene expression related to the innate immune system. We 
have reported that peroxisome proliferator-activated receptor γ (PPARγ), a nuclear 
receptor superfamily of ligand-activated transcription factors involved in lipid 
metabolism and anti-inflammatory activities, was down-regulated in the damaged bile 
ducts of PBC patients and speculated that increased susceptibility to biliary innate 
immunity is associated with the pathogenesis of cholangiopathy in PBC.12  
In addition to the biliary epithelial cells of PBC, a reduction of PPARγ expression 
in the colonic epithelial mucosa is reportedly associated with the pathogenesis of 
inflammatory bowel diseases (IBD).13-16 Furthermore, the expression of PPARγ is 
affected by the commensal intestinal flora and ligands (agonists) for PPARγ can attenuate 
colitis in IBD-model mice, supporting the notion that PPARγ ligands may have salutary 
effects on IBD.14,16-18 As for anti-inflammatory activities, the activation of PPARγ by its 
ligands is shown to inhibit the expression of pro-inflammatory cytokines, the induction 
of which is mediated via NF-κB and mitogen activated protein kinase (MAPK).17,19-23 
Several PPARγ ligands have been identified, including the prostaglandin D metabolite 
15-deoxy-Δ12,14-prostaglandin J2 (15d-PGJ2) and thiazolidinedione derivatives. Our 
previous study demonstrated that 15d-PGJ2 treatment attenuated LPS-induced NF-κB 
activation and also TNF-α production via an NF-κB-dependent pathway using cultured 
intrahepatic cholangiocarcinoma cells and biliary epithelial cells.12  
In this study, we examined anti-inflammatory effects of PPARγ ligands in vivo 
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using MRL/lpr mice with a naturally occurring PBC-like cholangitis to clarify possible 
therapeutic targets in biliary inflammation. 
 
 
MATERIALS AND METHODS 
PPARγ ligand 
 An endogenous ligand, 15d-PGJ2 (diluted by DMSO, Calbiochem, Darmstadt, 
Germany), was used as a PPARγ ligand.  
 
Animals 
 MRL/lpr mice bearing the lymphoproliferative gene lpr spontaneously develop 
severe autoimmune diseases including a systemic lupus erythematosus (SLE) and 
CNSDC-like cholangitis and produce an anti-mitochondrial antibody.24-26 This strain 
was used here as an animal model for autoimmune-mediated cholangitis similar to PBC. 
A total of 20 18-week-old MRL/lpr mice (male/female=10/10) were purchased from 
Japan SLC, Inc. (Shizuoka, Japan).  
 
Animal treatments 
  15d-PGJ2 was administered at low (400μg/kg/day) and high (1,000μg/kg/day) 
doses (5 mice each) for 3 weeks by intraperitoneal injection. The control group (n=10) 
received only vehicle (DMSO). After the animals were sacrificed, major organs were 
obtained and 4μm-thick sections of neutral formalin-fixed paraffin-embedded tissues 
were prepared for routine histologic observation and immunohistochemistry. The 
manipulation of these mice was done according to the Guidelines for the Care and Use 




 To evaluate the anti-inflammatory effect of PPARγ, major organs were examined 
histologically. For the liver, ten representative portal tracts containing interlobular bile 
ducts were chosen and portal inflammation including cholangitis in each was 
semiquantitatively evaluated as no or mild (score 0), moderate (score 1), or severe 
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(score 2).   
  
Immunohistochemistry 
 The deparaffinized and rehydrated sections used for studying CD3, and 
monocytes/macrophages and CD8 were treated with proteinase K and trypsin, 
respectively, while those used for CD79α were microwaved in 10mM citrate buffer for 
20min in a microwave oven. Following the blocking of endogenous peroxidase, these 
sections were incubated at 4ºC overnight with antibodies against CD3 (rat IgG, 10μg/ml, 
Millipore Headquarters, Billerica, MA), CD8 (rat IgG1, 2.5μg/ml, Chemicon, Tokyo), 
CD79α (rabbit IgG, 1.0μg/ml, Abcam Japan, Tokyo), and macrophage/monocyte (rat 
IgG, 2.5μg/ml, BMA Biomedicals, Augst, Switzerland) and then at room temperature for 
1h with a Simple Staining Kit (Nichirei, Tokyo). After a benzidine reaction, sections 
were lightly counterstained with hematoxylin. As a negative control, isotype-matched 
immunoglobulin was used as the primary antibody. 
 
Statistical analysis 




Histology of MRL/lpr mice 
  Variation in the incidence and degree of systemic lymphadenopathy, sialoadenitis, 
nephritis, pneumonia, arthritis, and hepatitis including cholangitis was found in 
MRL/lpr mice. In particular, sialoadenitis always occurred and the inflammation was 
extensive and destructive in most mice. In the liver, portal inflammation involving 
mononuclear cells was detected and portal tracts were cellularly enlarged. Moreover, 
chronic cholangitis resembling CNSDC was also found to varying degrees (Fig.1). 
 
Effect of 15d-PGJ2 
 In the group injected intraperitoneally with a low-dose of 15d-PGJ2, portal 
inflammation including cholangitis in interlobular bile ducts remained, the incidence 
and degree being similar to those in the controls (vehicle) (Fig.2CD). However, in the 
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high-dose group, the portal inflammation and cholangitis were attenuated and their 
incidence and degree were significantly reduced (Fig.2A). Almost no portal 
inflammation or cholangitis was found in one of the five mice in the high-dose group 
(Fig.2B). Semiquantitative evaluation demonstrated that inflammation was improved in 
the high-dose group (Fig.3), but not low-dose group. For sialoadenitis and pancreatitis, 
although some inflammatory damage remained, it was significantly less severe in the 
low-dose as well as high-dose group. For glomerulonephritis, there was no significant 
anti-inflammatory effect in 15d-PGJ2-injected mice. 
 
Analysis of inflammatory cells in portal tracts 
 To analyze the population of inflammatory cells in portal tracts of MRL/lpr mice 
and changes in the high-dose group, T cells, B cells, and macrophages were examined 
by immunohistochemistry. Few CD79α-positive B cells were found irrespective of 
15d-PGJ2-treatment, but many scattered CD3-positive T cells and 
monocytes/macrophages were detected (Figs.4 and 5). In particular, the number of 
CD3-positive T cells was clearly decreased in 15d-PGJ2-administered mice and this 
reduction was significant in portal tracts without inflammation (Fig.4). However, a few 
CD8-positive T cells were found irrespective of 15d-PGJ2-treatment, indicating the 
decreased of CD3-positive T cells is caused by that of CD4-positive T cells. A summary 




 We reported previously that PPARγ showing anti-inflammatory effects was 
constantly expressed in human biliary epithelial cells of intrahepatic small bile ducts 
including interlobular bile ducts and cultured human biliary epithelial cells.27 Moreover, 
the expression of PPARγ has been reported to be down-regulated by a Th1-dominant 
cytokine milieu and reduced in the damaged bile ducts of PBC patients.27 Based on 
these findings, we speculated that a Th1-dominant periductal cytokine milieu caused by 
CD4-positive T cells, following the reduction of PPARγ expression and increased 
susceptibility to several proinflammatory factors including innate immune responses is 
closely associated with the pathogenesis of cholangiopathy in PBC. Studies in vitro 
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have shown that functional PPARγ ligands suppress inflammatory responses by limiting 
the production of cytokines and chemokines secreted from macrophages and epithelial 
cells.16,28-30 PPARγ ligands are divided into endogenous types and thiazolidinedione 
derivatives. As one of the former, the prostaglandin D metabolite 15d-PGJ2 is well 
known and reported to attenuate the activation of NF-κB, a master regulator of 
inflammation, by preventing the phosphorylation of its inhibitor protein (I-κB).31 Our 
recent study demonstrated that 15d-PGJ2 treatment attenuated LPS-induced NF-κB 
activation and also TNF-α production via an NF-κB-dependent pathway in cultured 
intrahepatic cholangiocarcinoma cells and biliary epithelial cells.9,27  
 In this study, to verify whether PPARγ ligands show anti-inflammatory effects 
against portal inflammation including cholangitis in vivo, we used autoimmunity-prone 
mice, MRL/lpr. These mice have lymphoproliferative lesions caused by a deficiency of 
Fas (CD95) and spontaneously develop various forms of autoimmune disease in the 
same individuals, including glomerulonephritis, polyarteritis, arthritis and sialoadenitis 
associated with excessive production of autoantibodies.25 Therefore, MRL/lpr mice 
have been used as a model for the study of SLE, but also reported as a potentially 
suitable animal model of PBC.24,26 Although several clinical features including serum 
levels of total bilirubin and hepatobiliary enzymes including alanine aminotransferase 
(ALT), leucine aminopeptidase (LAP), and gamma-glutamyl transpeptidase (G-GTP) 
are incompatible with PBC, the serological and histopathological features including 
anti-mitochondrial antibody (AMA), cholangitis, and bile duct loss, indicate that 
MRL/lpr mice can be used as an experimental immune-mediated cholangitis model for 
PBC.24,26 This study demonstrated that the administration of 15d-PGJ2 (high-dose) 
could attenuate the degree of portal inflammation in MRL/lpr mice. Because the 
incidence of cholangitis was originally low and individual differences were significant, 
the anti-inflammatory effect was considered relatively mild as shown in Fig.3. However, 
the cholangitis and portal inflammation were completely absent in the mice given a 
high-dose of 15d-PGJ2, suggesting an anti-inflammatory effect of PPARγ on portal 
inflammation. Moreover, an evaluation of the proportion of inflammatory cells in portal 
tracts revealed as significant reduction in T cells in PPARγ-administered mice. 
Moreover, although we could not directly confirmed the decreased of CD4-positive T 
cells, because of no antibodies against mouse CD4 which are commercially available 
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and usable for formalin-fixed, paraffin-embedded section, the decreased of 
CD3-positive T cells was speculated to be caused by that of CD4-positive T cells from 
results of immunohistochemistry of CD3 and CD4. T cells, particularly autoreactive 
CD4-positive T cells, play an important role in the pathogenesis of cholangiopathy in 
cases of PBC.32 Therefore, because the PPARγ ligand had anti-inflammatory effects 
caused by the attenuation of CD4-positive T lymphocytes, it is likely to show as 
anti-inflammatory effect on cholangiopathy in PBC patients as well as MRL/lpr mice.  
In addition to cholangitis, sialoadenitis and pancreatitis in MRL/lpr mice were also 
improved by the low-dose as well as high-dose of 15d-PGJ2, suggesting that the 
sialoadenitis and pancreatitis are closely associated with PPARγ-dependent mechanism 
and show more susceptibility to PPARγ ligand, compared with cholangitis. However, as 
for the severity of glomerulonephritis, there was no significant anti-inflammatory effect 
in 15d-PGJ2-injected mice. In SLE, the deposition in kidney tissue of immune 
complexes and their interaction with macrophages is thought to trigger the 
inflammatory response leading to glomerulonephritis. Moreover, 
macrophage-dependent destruction in MRL/lpr mice is demonstrated in the 
pathogenesis of glomerulonephritis.33 As shown in Table 1 concerning the 
immunohistochemistry, the inflammation of monocyte/macrophage was less attenuated 
by the 15d-PGJ2 treatment, compared with that of T cells, speculating that 15d-PGJ2 
offers little benefit to the macrophage-dependent destruction such as glomerulonephritis 
in MRL/lpr mice. 
 Other PPARγ ligands include rosiglitazone, pioglitazone, troglitazone, and 
ciglitazone. Pioglitazone has been recently administered for diabetic mellitus and 
non-alcoholic steatohepatitis. Troglitazone had been used to treat diabetic mellitus and 
in one notable case, improved liver dysfunction in a patient with AMA-negative PBC.34 
It is no longer used because of its severe hepatotoxicity, but several effects of 
Troglitazone on inflammatory bowel diseases, carcinogenesis in the colon, diabetic 
mellitus, chronic pancreatitis, and sepsis in animal models have been reported 18,35-37. In 
this study, in addition to the anti-inflammatory activity of PPARγ in cultured human 
biliary epithelial cells, we demonstrated effected in vivo using MRL-lpr mice. This 
study is the first to assess the therapeutic role of a PPARγ ligand in inflammatory biliary 
diseases, particularly PBC. PPARγ ligands are potentially a new tool to restrain the 
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Table 1  
 
Summary of the population of inflammatory cells in portal tracts 
 
 
MRL/lpr mice           T cells         B cells   Monocyte/ 
                  CD3     CD8      CD79a   Macrophage 
 
Controls (DMSO)    ++        ±   ±       ++ 
 
15d-PGJ2-treated   ± ～ +     ±   ±      + ～ ++ 
(high-dose) 
 
±：none or a few，＋：some，＋＋：many  
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Fig.1  The MRL/lpr mouse at 21 weeks. Marked portal inflammation involving 
lymphoid cells and non-suppurative destructive cholangitis-like lesions with 
irregular biliary epithelial polarity (arrow) are found.  





Fig.2  MRL/lpr mice 21 weeks after the administration of high-dose 15d-PGJ2 
(1,000μg/kg/day) for 3 weeks (A and B) and controls (DMSO, C and D). A and 
B show the high-dose group in which portal inflammation remains (arrow) and 
has completely disappeared, respectively. C and D are controls. Most portal 
tracts exhibit significant inflammation (C) and mild bile duct damage (arrow, D) 
with infiltration by lymphocytes and macrophages.  




Fig.3  Semiquantitative evaluation of portal inflammation. Ten representative portal 
tracts were chosen in each mouse and the inflammation in each was evaluated 
(score 0, 1, or 2). The average score of MRL-lpr mice treated with high-dose 
15d-PGJ2 (0.48±0.11 [mean±S.E.M]) is significantly reduced, compared with 
the control (DMSO, 0.24±0.07). *, p<0.05. 




Fig.4  Immunohistochemistry of CD3 in MRL-lpr mice treated with vehicle (DMSO, 
A) and high-dose 15d-PGJ2 (B and C). In the control groups, CD3-positive T 
cells are found in enlarged portal tracts (A). In the high-dose 15d-PGJ2 group, 
marked inflammation remains in portal tracts, but CD3-positive T cell numbers 
are significantly decreased (B), compared with controls (A). The portal tracts of 
the high-dose 15d-PGJ2 group contain few CD3-positive T cells (C).  




Fig.5  Immunohistochemistry of monocytes/macrophages in MRL-lpr mice treated 
with vehicle control (DMSO, A) and high-dose 15d-PGJ2 (B and C). Many 
monocytes/macrophages are found in inflammed portal tracts in both the control 
and high-dose 15d-PGJ2 groups (A and B, respectively). The portal tracts of the 
high-dose 15d-PGJ2 group still contain several monocytes/macrophages (C). 






